[go: up one dir, main page]

MX2010000724A - Metodo para reducir presion intracraneal. - Google Patents

Metodo para reducir presion intracraneal.

Info

Publication number
MX2010000724A
MX2010000724A MX2010000724A MX2010000724A MX2010000724A MX 2010000724 A MX2010000724 A MX 2010000724A MX 2010000724 A MX2010000724 A MX 2010000724A MX 2010000724 A MX2010000724 A MX 2010000724A MX 2010000724 A MX2010000724 A MX 2010000724A
Authority
MX
Mexico
Prior art keywords
intracranial pressure
reducing intracranial
subject
methods
present
Prior art date
Application number
MX2010000724A
Other languages
English (en)
Inventor
Robert Vink
Original Assignee
Adelaide Res & Innovation Pty
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2007903902A external-priority patent/AU2007903902A0/en
Application filed by Adelaide Res & Innovation Pty filed Critical Adelaide Res & Innovation Pty
Publication of MX2010000724A publication Critical patent/MX2010000724A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invención se relaciona de manera general con métodos para reducir la presión intracraneal en un sujeto. De manera más particular, los métodos de la presente invención incluyen administrar al sujeto una cantidad efectiva de un antagonista del receptor de la sustancia P.
MX2010000724A 2007-07-19 2008-07-18 Metodo para reducir presion intracraneal. MX2010000724A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2007903902A AU2007903902A0 (en) 2007-07-19 Method for reducing intracranial pressure
PCT/AU2008/001033 WO2009009829A1 (en) 2007-07-19 2008-07-18 Method for reducing intracranial pressure

Publications (1)

Publication Number Publication Date
MX2010000724A true MX2010000724A (es) 2010-06-02

Family

ID=40259214

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010000724A MX2010000724A (es) 2007-07-19 2008-07-18 Metodo para reducir presion intracraneal.

Country Status (9)

Country Link
US (1) US20100184819A1 (es)
EP (1) EP2187890A4 (es)
JP (1) JP2010533655A (es)
KR (1) KR20100055430A (es)
CN (1) CN101795690A (es)
AU (1) AU2008278273A1 (es)
CA (1) CA2700477A1 (es)
MX (1) MX2010000724A (es)
WO (1) WO2009009829A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3016659A4 (en) * 2013-07-02 2017-03-15 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) Method for preventing and/or treating chronic traumatic encephalopathy-iii
US10729677B2 (en) 2013-07-02 2020-08-04 Eustralis Pharmaceutical Limited (Trading As Pressura Neuro) Method for preventing and/or treating chronic traumatic encephalopathy-I
JP7053614B2 (ja) 2016-11-28 2022-04-12 エスエイチエル・メディカル・アーゲー 物質を投与する装置
EP3624885A4 (en) 2017-05-19 2021-03-10 Trudell Medical International EXPIRATORY OVERPRESSURE DEVICE
EP3746077A4 (en) * 2018-02-02 2021-10-27 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) PARENTERAL FORMULATIONS AND THEIR USES
JP2021512869A (ja) * 2018-02-02 2021-05-20 ユーストラリス ファーマシューティカルズ リミテッド （トレーディング アズ プレススラ ニューロ） 経口製剤及びその使用
USD903097S1 (en) 2018-05-18 2020-11-24 Trudell Medical International Mask
USD874064S1 (en) 2018-05-18 2020-01-28 Trudell Medical International Mask
USD893806S1 (en) 2018-11-09 2020-08-18 Trudell Medical Internationl Mask and shroud
WO2020225283A1 (en) * 2019-05-08 2020-11-12 Plus Vitech, S.L. Nk1 inhibitors for the treatment of malaria
WO2021035289A1 (en) * 2019-08-23 2021-03-04 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Therapeutic methods and uses thereof
JP7593648B2 (ja) 2019-12-03 2024-12-03 国立大学法人 新潟大学 水頭症の予防又は治療薬及び水頭症の予防又は治療用医薬組成物
WO2021202286A1 (en) * 2020-03-30 2021-10-07 Dignify Therapeutics, Llc Compositions and methods for treating autonomic dysreflexia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0776573A (ja) * 1993-07-14 1995-03-20 Takeda Chem Ind Ltd ヘテロ環化合物、その製造法および剤
EP0634402A1 (en) * 1993-07-14 1995-01-18 Takeda Chemical Industries, Ltd. Isochinolinone derivatives, their production and use
TW382017B (en) * 1995-12-27 2000-02-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
AUPQ514600A0 (en) * 2000-01-18 2000-02-10 James Cook University Brain injury treatment
EP1401838B1 (en) * 2001-06-12 2014-03-26 Janssen Pharmaceutica NV Novel substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury

Also Published As

Publication number Publication date
CN101795690A (zh) 2010-08-04
EP2187890A1 (en) 2010-05-26
EP2187890A4 (en) 2011-09-07
JP2010533655A (ja) 2010-10-28
WO2009009829A1 (en) 2009-01-22
US20100184819A1 (en) 2010-07-22
AU2008278273A1 (en) 2009-01-22
KR20100055430A (ko) 2010-05-26
CA2700477A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
MX2010000724A (es) Metodo para reducir presion intracraneal.
IL238437A0 (en) Method for preparing 3-aryl-5-trifluoromethyl-5,4-dihydro-isoxazoles
MX339878B (es) Nuevas formas solidas de clorhidrato de bendamustina.
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
MY171841A (en) Antibody formulation
PH12014501108A1 (en) Anti-il-36r antibodies
PL2271604T3 (pl) Sposób wytwarzania 2,3,3,3-tetrafluoro-1-propenu
PL2324908T3 (pl) Sposób, jego wykorzystanie oraz urządzenie do dodawania dodatków do pasz
GEP20135903B (en) Method of (1s, 2r)-milnacipran synthesis
SI2238110T1 (sl) Derivati 5,6-bisaril-2-piridin-karboksamida, njihova priprava in njihova terapevtska uporaba kot antagonisti receptorjev urotenzina II
UA102097C2 (ru) Способ лечения воспалительного заболевания с применением соединения, которое нейтрализует gm-csf, и соединения, которое нейтрализует il-17
MX2010010339A (es) Ciclohexildiaminas sustituidas.
TW201129620A (en) New formaldehyde scavengers
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.
UA103197C2 (uk) Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами
EP2446885A4 (en) THERAPY FOR HYPERTONIA OR NORMAL HIGH BLOOD PRESSURE
MY161655A (en) Unit dosage of apadenoson
IL189813A0 (en) Garment for relieving back discomfort
ZA201101961B (en) Method for preparing 1,6:2,3-dianhydro-beta-d-mannopyranose
WO2010033862A3 (en) Methods for treating cancer using npar agonists
MX356969B (es) Producto lácteo bajo en colesterol para usarse en el tratamiento y/o prevención de una enfermedad hepática.
UA88561C2 (ru) Способ получения антигемолитического препарата
UA96037C2 (ru) Применение антагониста рецепторов интерлейкина-1 как средства антиалкогольного действия
UA96634C2 (ru) Применение антагониста рецепторов интерлейкина-1 (арил-1) как средства с гипоурикемическим действием
UA33415U (ru) Способ диагностики радиационного поражения мозга

Legal Events

Date Code Title Description
FA Abandonment or withdrawal